Mesoblast phase 3 trial shows that a single injection of rexlemestrocel-l + hyaluronic acid carrier results in at least two years of pain reduction with opioid sparing activity in patients with chronic low back pain due to degenerative disc disease

New york, feb. 10, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the phase 3 randomized controlled trial of its allogeneic mesenchymal precursor cell (mpc) therapy rexlemestrocel-l in 404 enrolled patients with chronic low back pain (clbp) due to degenerative disc disease (ddd) refractory to conventional treatments. the results indicate that a single injection of rexlemestrocel-l may provide a safe, durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease, and that greatest benefits are seen when administered earlier in the disease process before irreversible fibrosis of the intervertebral disc has occurred.
MESO Ratings Summary
MESO Quant Ranking